Retatrutide is a next-generation research peptide that has drawn considerable attention because of its triple receptor activity. Where earlier incretin peptides target one or two receptors, retatrutide is studied as an agonist at three.

A triple-agonist profile

Retatrutide is investigated for simultaneous activity at:

The GLP-1 receptor
The GIP receptor
The glucagon receptor

This three-way profile is what distinguishes it from single-agonist semaglutide and dual-agonist tirzepatide, making it a compelling comparator in incretin-pathway studies. It sits within our weight-management research category.

Why researchers study it separately

Adding glucagon-receptor engagement introduces a distinct axis of metabolic signalling into a model. Because of that, retatrutide is treated as its own reference standard rather than a variation on existing peptides — its structure, molecular weight and behaviour are unique.

Reference-standard considerations

As a newer and structurally complex peptide, verified identity and purity are especially important. Confirm the molecular weight against the certificate of analysis and store the lyophilised material cold until use.

Frequently asked questions

What makes retatrutide a "triple agonist"?

In research it is studied for activity at three receptors — GLP-1, GIP and glucagon — whereas semaglutide targets one and tirzepatide two.

How does retatrutide differ from tirzepatide?

Tirzepatide is a dual GLP-1/GIP agonist; retatrutide adds glucagon-receptor activity, giving it a distinct three-receptor research profile.

Is retatrutide available for human use?

No. It is supplied as a research reference standard for laboratory use only.

Every HK Peptide reference standard is HPLC-verified with third-party Janoshik lab reports available on request. Browse the full catalogue or view our certificates of analysis.

Research use only. This article is educational and written for laboratory and research audiences. HK Peptide reference materials are supplied strictly for in-vitro and other non-human research. Nothing here is medical advice, and none of these compounds are intended for human consumption or to diagnose, treat, cure, or prevent any condition.